ORIGINAL ARTICLES: Clinical researchMetastatic uveal melanoma is there a role for conventional chemotherapy? – A single center study based on 58 patientsPons, Francesca; Plana, Mariaa; Caminal, Josep Mariae; Pera, Joanb; Fernandes, Isabelh; Perez, Javierc; Garcia-del-Muro, Xaviera; Marcoval, Joaquimf; Penin, Rosag; Fabra, Angelsd; Piulats, Josep MariaaAuthor Information aDepartments of Medical Oncology bRadiotherapy cClinical Research Unit, Institut Català d'Oncologia-IDIBELL dCentre d'Oncologia Molecular-IDIBELL eDepartments of Ophtalmology fDermathology gPathology, Hospital de Bellvitge, Barcelona, Spain hDepartment of Medical Oncology, Hospital Santa Maria, Lisbon, Portugal Correspondence to Josep Maria Piulats, MD, PhD, Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, Hospital Duran I Reynals, Avda Gran Via 199-203, L'Hospitalet de Llobregat, Barcelona 08907, Spain Tel: +34 93 260 7744; fax: +34 93 260 7741; e-mail: [email protected]Francesc Pons and Maria Plana contributed equally to this study Received December 11, 2010 Accepted February 7, 2011 Melanoma Research: June 2011 - Volume 21 - Issue 3 - p 217-222 doi: 10.1097/CMR.0b013e3283457726 Buy Metrics Abstract Uveal melanoma metastases develop in 6.5–35% of patients, most commonly to the liver. Metastatic uveal melanoma (MUM) survival is poor, with 5–7 months of median survival. We reviewed retrospectively all patients with MUM diagnosed between January 1990 and December 2008 at our institution. We analyzed a total of 58 patients with a median age of 61 years (31–84 years). Median time for metastases development was 25.63 months (0.17–102.43 months). Fifty-six patients had hepatic involvement, 63.8% bilobar and 51.7% had more than or equal to five hepatic metastatic lesions. Sixteen patients (27.6%) had two or more organs involved. Six patients (10.71%) were treated with surgery, 25 patients (44.67%) received systemic chemotherapy, and 23 (41.07%) had best supportive care (BSC). The median overall survival (OS) for all the patients was 10.83 months [95% confidence interval (CI): 6.92–14.74]. Patients who had undergone chemotherapy presented 10.83 months (95% CI: 5.35–16.308) of median OS whereas the patients who did not undergo this treatment had an OS of 8.033 months (95% CI: 2.46–13.61). There were more patients with poor survival characteristics such as worse Eastern Cooperative Oncology Group performance status in the BSC group. OS was poor in treated and BSC patients. Differences in survival are more likely to be related to patient characteristics rather than to a chemotherapy effect. Patients with MUM should be included in clinical trials evaluating other options with newer agents. © 2011 Lippincott Williams & Wilkins, Inc.